Lv41
530 积分 2023-11-14 加入
Bispecific antibody takes a BiTE out of B cells in rheumatoid arthritis
13天前
已完结
IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer
14天前
已完结
Recent Advances of Second‐Line Targeted Biopharmaceutical Therapies in Thyroid Associated Ophthalmopathy
1个月前
已完结
Bispecific T cell engager therapy for refractory rheumatoid arthritis
3个月前
已完结
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
5个月前
已完结
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study
5个月前
已完结
IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma
6个月前
已完结
Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)
11个月前
已完结
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
11个月前
已完结
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
1年前
已完结
皖公网安备34019202002308
